These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34653245)

  • 1. Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results.
    Withanage K; De Coster I; Cools N; Viviani S; Tourneur J; Chevandier M; Lambiel M; Willems P; Le Vert A; Nicolas F; Van Damme P
    J Infect Dis; 2022 Aug; 226(1):119-127. PubMed ID: 34653245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine.
    Leroux-Roels I; Waerlop G; Tourneur J; De Boever F; Maes C; Bruhwyler J; Guyon-Gellin D; Moris P; Del Campo J; Willems P; Leroux-Roels G; Le Vert A; Nicolas F
    Front Immunol; 2022; 13():852904. PubMed ID: 35464450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: a randomised, double-blind, placebo-controlled, phase 2a trial.
    Leroux-Roels I; Willems P; Waerlop G; Janssens Y; Tourneur J; De Boever F; Bruhwyler J; Alhatemi A; Jacobs B; Nicolas F; Leroux-Roels G; Le Vert A
    Lancet Infect Dis; 2023 Dec; 23(12):1360-1369. PubMed ID: 37517422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OVX836 Heptameric Nucleoprotein Vaccine Generates Lung Tissue-Resident Memory CD8+ T-Cells for Cross-Protection Against Influenza.
    Del Campo J; Bouley J; Chevandier M; Rousset C; Haller M; Indalecio A; Guyon-Gellin D; Le Vert A; Hill F; Djebali S; Leverrier Y; Marvel J; Combadière B; Nicolas F
    Front Immunol; 2021; 12():678483. PubMed ID: 34177921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
    Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
    Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial.
    Evans TG; Bussey L; Eagling-Vose E; Rutkowski K; Ellis C; Argent C; Griffin P; Kim J; Thackwray S; Shakib S; Doughty J; Gillies J; Wu J; Druce J; Pryor M; Gilbert S
    Lancet Infect Dis; 2022 Jun; 22(6):857-866. PubMed ID: 35305317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes.
    Del Campo J; Pizzorno A; Djebali S; Bouley J; Haller M; Pérez-Vargas J; Lina B; Boivin G; Hamelin ME; Nicolas F; Le Vert A; Leverrier Y; Rosa-Calatrava M; Marvel J; Hill F
    NPJ Vaccines; 2019; 4():4. PubMed ID: 30701093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial.
    van Doorn E; Pleguezuelos O; Liu H; Fernandez A; Bannister R; Stoloff G; Oftung F; Norley S; Huckriede A; Frijlink HW; Hak E
    BMC Infect Dis; 2017 Apr; 17(1):241. PubMed ID: 28376743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials.
    Feldman RA; Fuhr R; Smolenov I; Mick Ribeiro A; Panther L; Watson M; Senn JJ; Smith M; Almarsson Ӧ; Pujar HS; Laska ME; Thompson J; Zaks T; Ciaramella G
    Vaccine; 2019 May; 37(25):3326-3334. PubMed ID: 31079849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico.
    López-Macías C; Ferat-Osorio E; Tenorio-Calvo A; Isibasi A; Talavera J; Arteaga-Ruiz O; Arriaga-Pizano L; Hickman SP; Allende M; Lenhard K; Pincus S; Connolly K; Raghunandan R; Smith G; Glenn G
    Vaccine; 2011 Oct; 29(44):7826-34. PubMed ID: 21816199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity, Safety, and Efficacy of a Standalone Universal Influenza Vaccine, FLU-v, in Healthy Adults: A Randomized Clinical Trial.
    Pleguezuelos O; Dille J; de Groen S; Oftung F; Niesters HGM; Islam MA; Næss LM; Hungnes O; Aldarij N; Idema DL; Perez AF; James E; Frijlink HW; Stoloff G; Groeneveld P; Hak E
    Ann Intern Med; 2020 Apr; 172(7):453-462. PubMed ID: 32150750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
    Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
    PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study.
    Liebowitz D; Gottlieb K; Kolhatkar NS; Garg SJ; Asher JM; Nazareno J; Kim K; McIlwain DR; Tucker SN
    Lancet Infect Dis; 2020 Apr; 20(4):435-444. PubMed ID: 31978354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-blind, multi-center, phase III clinical trial to evaluate the immunogenicity and safety of MG1109 (egg-based pre-pandemic influenza A/H5N1 vaccine) in healthy adults.
    Song JY; Choi MJ; Noh JY; Choi WS; Cheong HJ; Wie SH; Lee JS; Woo GJ; Lee SH; Kim WJ
    Hum Vaccin Immunother; 2017 May; 13(5):1190-1197. PubMed ID: 27996363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2/3 double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a seasonal trivalent inactivated split-virion influenza vaccine (IVACFLU-S) in healthy adults in Vietnam.
    Lan PT; Toan NT; Thang HA; Thang TC; Be LV; Thai DH; Huong VM; Nga NT; Tang Y; Holt R; Francesco BS; Flores J; Tewari T
    Hum Vaccin Immunother; 2019; 15(12):2933-2939. PubMed ID: 31070986
    [No Abstract]   [Full Text] [Related]  

  • 17. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial.
    Pleguezuelos O; Robinson S; Stoloff GA; Caparrós-Wanderley W
    Vaccine; 2012 Jun; 30(31):4655-60. PubMed ID: 22575166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.
    Baden LR; Stieh DJ; Sarnecki M; Walsh SR; Tomaras GD; Kublin JG; McElrath MJ; Alter G; Ferrari G; Montefiori D; Mann P; Nijs S; Callewaert K; Goepfert P; Edupuganti S; Karita E; Langedijk JP; Wegmann F; Corey L; Pau MG; Barouch DH; Schuitemaker H; Tomaka F;
    Lancet HIV; 2020 Oct; 7(10):e688-e698. PubMed ID: 33010242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.
    Westritschnig K; Hochreiter R; Wallner G; Firbas C; Schwameis M; Jilma B
    Hum Vaccin Immunother; 2014; 10(1):170-83. PubMed ID: 24064511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.